C
China National Accord Medicines Corp Ltd
SZSE:000028
China National Accord Medicines Corp Ltd
SZSE:000028
Price:
38.6 CNY
-0.97%
Market Closed
Updated:
May 21, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
12
Current
10.7
Median
13.1
Industry
Higher
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=12
Enterprise Value
/
28.4B
EBITDA
2.4B
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| CN |
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
21.5B CNY | 12 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
72.4B USD | 16.1 | |
| US |
|
Cencora Inc
NYSE:COR
|
43.2B USD | 11.5 | |
| US |
|
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 11.3 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
23.5B USD | 8.7 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.4B USD | 12.4 | |
| KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 59.9 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
66.9B HKD | 1.7 | |
| IT |
|
Amplifon SpA
MIL:AMP
|
7.5B EUR | 15.2 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
57.5B CNY | 14.9 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
52B CNY | 8.5 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
8.9
2-Years Forward
EV/EBITDA
8.4
3-Years Forward
EV/EBITDA
7.8
You don't have any saved screeners yet
